ProKidney (PROK)
NASDAQ:PROK
Want to see PROK full AI Analyst Report?
Top Page
ProKidney
(NASDAQ:PROK)
Select Model
Select Model
Rating:45Neutral
Price Target:
$2.00
▼(-8.26% Downside)
Action:ReiteratedDate:04/18/26
The score is primarily constrained by weak financial performance—minimal revenue, large losses, and significant cash burn—despite low debt and improved 2025 equity. Technicals are mixed with modest near-term strength but a still-challenged longer-term trend, and valuation support is limited due to negative earnings and no dividend. A positive Phase 3 trial enrollment update helps, but the key milestones are years out.
Positive Factors
Phase 3 Progress
Advancing a lead asset into a larger, maintained-power Phase 3 reduces statistical and regulatory uncertainty over time. A clear two-stage readout plan (surrogate then confirmatory) creates a defined clinical pathway, improving long-term program credibility and strategic planning for partnerships or commercialization.
Negative Factors
Heavy Cash Burn
Persistent, large negative operating and free cash flow indicates the company will remain dependent on external financing for the foreseeable future. This structural cash burn increases dilution and constrains strategic choices, forcing tradeoffs between funding R&D, partnerships, or commercialization investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase 3 Progress
Advancing a lead asset into a larger, maintained-power Phase 3 reduces statistical and regulatory uncertainty over time. A clear two-stage readout plan (surrogate then confirmatory) creates a defined clinical pathway, improving long-term program credibility and strategic planning for partnerships or commercialization.
Read all positive factors
ProKidney (PROK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$582.70M
Dividend YieldN/A
Average Volume (3M)1.00M
Price to Earnings (P/E)―
Beta (1Y)2.36
Revenue Growth1075.00%
EPS Growth18.02%
CountryUS
Employees204
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.52
Shares Outstanding141,942,900
10 Day Avg. Volume1,413,634
30 Day Avg. Volume1,001,539
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)-0.30
Price to Sales (P/S)335.98
P/FCF Ratio-2.22
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue491.28
Enterprise Value/Gross Profit-224.52
Enterprise Value/Ebitda-2.96
Forecast
1Y Price Target
$7.33Price Target Upside236.39% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-0.71
Revenue Forecast (FY)$303.67K
ProKidney Business Overview & Revenue Model
Company Description
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phas...
How the Company Makes Money
As a clinical-stage company, ProKidney’s ability to generate recurring product revenue depends on obtaining regulatory approval and commercializing its investigational therapies; product sales revenue is null. Historically, the company’s revenue h...
ProKidney Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
21
Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 893.00K | 76.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -4.83M | 76.00K | 0.00 | -3.04M | 0.00 |
| EBITDA | -158.97M | -158.49M | -125.59M | -143.99M | -53.12M |
| Net Income | -68.99M | -61.19M | -35.47M | -108.03M | -55.15M |
Balance Sheet | |||||
| Total Assets | 335.57M | 441.07M | 420.55M | 518.00M | 40.30M |
| Cash, Cash Equivalents and Short-Term Investments | 270.02M | 358.29M | 362.95M | 490.25M | 20.56M |
| Total Debt | 2.96M | 3.24M | 4.41M | 2.40M | 1.33M |
| Total Liabilities | 34.78M | 39.44M | 29.22M | 13.06M | 13.38M |
| Stockholders Equity | -1.01B | -994.95M | -1.10B | -1.10B | 26.92M |
Cash Flow | |||||
| Free Cash Flow | -135.31M | -155.86M | -124.27M | -78.94M | -55.49M |
| Operating Cash Flow | -120.12M | -126.35M | -90.07M | -77.09M | -50.30M |
| Investing Cash Flow | 103.97M | 20.41M | -329.98M | -1.74M | -5.19M |
| Financing Cash Flow | 25.57M | 144.41M | -9.55M | 548.52M | 71.47M |
ProKidney Technical Analysis
Positive
2.18
Price Trends
2.04
Positive
2.14
Positive
2.45
Negative
Market Momentum
-0.01
Negative
60.43
Neutral
87.64
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PROK, the sentiment is Positive. The current price of 2.18 is above the 20-day moving average (MA) of 1.86, above the 50-day MA of 2.04, and below the 200-day MA of 2.45, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 60.43 is Neutral, neither overbought nor oversold. The STOCH value of 87.64 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PROK.
ProKidney Risk Analysis
ProKidney disclosed 91 risk factors in its most recent earnings report. ProKidney reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ProKidney Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $953.96M | -7.50 | 55.14% | ― | 150.30% | 59.74% | |
53 Neutral | $1.12B | -7.34 | 170.21% | ― | 21.45% | 0.35% | |
53 Neutral | $1.74B | -5.04 | -64.21% | ― | 27.23% | -12.53% | |
52 Neutral | $2.41B | -5.25 | -43.17% | ― | 53.45% | 32.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $315.80M | -2.69 | -64.81% | ― | ― | 24.34% | |
45 Neutral | $582.70M | -3.93 | 6.86% | ― | 1075.00% | 18.02% |
* Healthcare Sector Average
PROK
ProKidney
1.88
1.13
150.67%
RZLT
Rezolute
3.30
-0.82
-19.90%
URGN
Urogen Pharma
23.29
12.34
112.69%
PHAT
Phathom Pharmaceuticals
12.87
10.29
398.84%
RLAY
Relay Therapeutics
13.09
9.77
294.28%
NRIX
Nurix Therapeutics
16.93
5.99
54.75%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.